NCT06573008View on ClinicalTrials.gov

Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications

PHASE3RecruitingINTERVENTIONAL
Enrollment

328

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Influenza, Human
Interventions
DRUG

GP681 40mg

2 x 20mg tablets taken orally

DRUG

GP681 Simulant

Placebo tablets matching GP681 40mg

Trial Locations (1)

Unknown

RECRUITING

The people's Hospital of Chizhou, Chizhou

Sponsors
All Listed Sponsors
lead

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

INDUSTRY